A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function

Tazemetostat is an investigational drug that kills cancer cells by stopping a gene called EZH2 from working. EZH2 affects how two other genes, INI1 and SMARCA4 work in cells.

In early clinical development, tazemetostat has demonstrated clinical activity and a generally well-tolerated safety profile in both patients with hematological malignancies and genetically defined solid tumors.

Currently, tazemetostat is being used as a single-agent therapy in multiple clinical trials, including Phase 2 clinical trials in patients with mesothelioma.

Please click on this link to determine your eligibility and latest clinical trial locations.

Categories:

Our Mission

Medical Empowerment

Get the information you need to make informed decisions about your treatment.

Learn More
Legal Empowerment

Get the compensation you need to address the financial cost of your illness.

Learn More
Going For The Gold

Helping empower our clients with over $2.5 Billion in recoveries. We fight for our clients!

Settlements & Verdicts
Giving Back To The Community

Unprecedented Support for Mesothelioma Research. See how we can help!

Our Contributions

Get Empowered

We put your medical and personal needs first and provide compassionate representation.

First Name
Please enter your first name.
Last Name
Please enter your last name.
Phone
Please enter your phone number.

This isn't a valid phone number.
Email
Please enter your email address.

This isn't a valid email address.
Are you a new client?
Please make a selection.
How can we help you?
Please enter a message.
By submitting, you agree to be contacted about your request & other information using automated technology. Message frequency varies. Msg & data rates may apply. Text STOP to cancel. Acceptable Use Policy